This move is archived. Current quotes and coverage live on the stock page.
Get HBP alerts:
Helix BioPharma Corp. faces a significant downturn, with shares dropping 5.70% in the last trading session.
Helix BioPharma Corp. (HBP.TO) saw its stock price close at CA$1.49 after a 5.70% decline in the last trading session. This drop raises concerns about the company's current situation and future in the biotech sector, especially since there hasn't been any recent positive news to boost investor confidence.
Advertisement
Helix BioPharma Corp.
HBP.TO
HBP.TO
Helix BioPharma Corp.
WealthAwesomeMarket cap
$124.50M
52W high
$5.40
52W low
$1.10
1W change
-17.84%
Beta
-0.27
Analyst Price Targets
Based on analyst covering HBP
Wall Street analysts forecast HBP stock price to rise 64.5% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.50
+64.5% Upside
Current Price
C$1.52
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HBP's historical volatility
30-Day Vol
77.3%
Annualized
90-Day Vol
66.9%
Annualized
Trend (90d)
+8.4%
Annualized drift
90d Mean
C$1.57
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$1.54 | C$1.18 โ C$2.00 |
| 60 trading days | C$1.55 | C$1.06 โ C$2.26 |
| 90 trading days | C$1.57 | C$0.99 โ C$2.49 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should be cautious as Helix BioPharma's stock struggles amid a lack of recent developments and declining market sentiment.
Helix BioPharma Corp. stock down 5.70% in one day
The company's market cap now stands at CA$120.68 million, reflecting investor caution due to ongoing operational challenges.
Bull case
If Helix BioPharma can successfully navigate its upcoming financial reporting and show progress in its clinical trials, it could attract investor interest and stabilize its stock price.
Bear case
Ongoing investor skepticism, along with the lack of significant news or developments, may lead to further declines in Helix BioPharma's stock, especially if the financial results fall short of expectations.
Advertisement
Market Reaction to Helix BioPharma Corp.
The recent drop in Helix BioPharma's stock price is linked to market sentiment and the absence of positive news. With the stock closing at CA$1.49, investors are feeling the pressure as the company's market cap hovers around CA$120.68 million. Without significant news to spark interest, the stock's performance remains a concern for both current and potential investors. For more details on Helix BioPharma's financials, check out our analysis on HBP.TO.
The Importance of Upcoming Financial Reports
Helix BioPharma is set to release its interim financial statements soon, which could shed light on its operational performance. Investors will be closely watching these results to assess the company's health and future prospects. A disappointing report could worsen the current downturn, while positive results might help stabilize the stock. For ongoing updates on Helix BioPharma, visit our page on HBP.TO.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
